Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes

The Lancet Neurology

Volumn 10, Issue 4, 2011, Pages 338-348

  Coles, Alasdair J ^a   Fox, Edward ^b   Vladic, Anton ^c   Gazda, Suzanne K ^d   Brinar, Vesna ^e   Selmaj, Krzysztof W ^f   Bass, Ann Doan Do ^h   Wynn, Daniel R ^g   Margolin, David H ⁱ   Lake, Stephen L ⁱ   Moran, Susan ⁱ   Palmer, Jeffrey ⁱ   Smith, M Shelton ^j   Compston, D Alastair S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MS Clinic of Central Texas   (United States)

^c Croatian Academy of Medical Sciences   (Croatia)

^d Clinical Research   (United States)

^e KBC Zagreb   (Croatia)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g MS Center   (United States)

^h Hand Center of San Antonio   (United States)

ⁱ GENZYME CORPORATION   (United States)

^j ReSearch Pharmaceutical Services   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON;

ADULT; AGE; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENDER; HUMAN; IMMUNOMODULATION; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 79952740129     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70020-5     Document Type: Article

References (10)

1. Xia MQ, Hale G, Lifely MR, Ferguson MAJ, Campbell D, Packman L Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993, 293:633-640.
2. Cox AL, Thompson SAJ, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005, 35:3332-3342.
3. Thompson SAJ, Jones JL, Cox AL, Compston DAS, Coles AJ B-cell reconstitution and BAFF after alemtuzumab. J Clin Immunol 2010, 30:99-105.
4. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006, 253:98-108.
5. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801. CAMMS223 Trial Investigators.
6. Fox E, Sullivan H, Gazda S Open-label, single-arm, phase 2 study of alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed beta-interferon therapies. Neurology 2007, 68:A274-A275.
7. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
8. Munschauer F, Giovannoni G, Lublin F, et al. Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Mult Scler 2008, 14:S167-S168.
9. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009, 8:254-260.
10. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010, 133:2232-2247.